Trade Sage Therapeutics, Inc. - SAGE CFD

Sage Therapeutic Company profile

About SAGE Therapeutics Inc

SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).

Equity composition

Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.